Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia

QR Code

Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia

Srihari Gopal1, Joris Berwaerts1, Isaac Nuamah1, Kasem Akhras2, Danielle Coppola1, Ella Daly1, David Hough1, Joseph Palumbo11Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LLC, Raritan, NJ, USA; 2Johnson &amp; Johnson Pharmaceutical Services, LLC, Raritan, N...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Srihari Gopal, Joris Berwaerts, Isaac Nuamah, et al
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2011
Sujets:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/45d7582590bb4d0e9e153426d5bfd21f
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm
par: Citrome L, et autres
Publié: (2019)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
par: Mathews M, et autres
Publié: (2019)

Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies
par: Srihari Gopal, et autres
Publié: (2017)

Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose
par: Samtani MN, et autres
Publié: (2013)

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
par: Mathews M, et autres
Publié: (2018)

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
par: Savitz AJ, et autres
Publié: (2019)

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
par: O'Donnell A, et autres
Publié: (2021)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
par: Zhang F, et autres
Publié: (2015)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
par: Takada R, et autres
Publié: (2018)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
par: Nash AI, et autres
Publié: (2019)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
par: Lopez A, et autres
Publié: (2019)

The twenty-ninth day: Accommodating human needs and numbers to the earth's resources
par: Brown, Lester Russell, 1934-
Publié: (1978)

Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability
par: Gattaz WF, et autres
Publié: (2020)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
par: Sliwa JK, et autres
Publié: (2012)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
par: Emsley R, et autres
Publié: (2018)

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
par: Savitz AJ, et autres
Publié: (2017)

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia
par: Lambert M, et autres
Publié: (2020)

Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
par: El Khoury AC, et autres
Publié: (2021)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
par: Such P, et autres
Publié: (2021)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
par: Si T, et autres
Publié: (2019)

Availability and use of number needed to treat (NNT) based decision aids for pharmaceutical interventions
par: Cassandra Nguyen, et autres
Publié: (2021)

Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia
par: Takahashi N, et autres
Publié: (2013)

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
par: Gopal S, et autres
Publié: (2020)

Direct squencing from the minimal number of DNA molecules needed to fill a 454 picotiterplate.
par: Mária Džunková, et autres
Publié: (2014)

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
par: Di Lorenzo R, et autres
Publié: (2019)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
par: Alphs L, et autres
Publié: (2013)

Do No Harm: The Urgent Need to Reform Short-Term Global Health Experiences
par: Keith Martin
Publié: (2019)

The cost reduction in hospitalization associated with paliperidone palmitate in the People’s Republic of China, Korea, and Malaysia
par: Chiou CF, et autres
Publié: (2015)

CT Examinations for COVID-19: A Systematic Review of Protocols, Radiation Dose, and Numbers Needed to Diagnose and Predict
par: Jong Hyuk Lee, et autres
Publié: (2021)

Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study
par: Si TM, et autres
Publié: (2015)

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
par: Emsley R, et autres
Publié: (2017)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
par: Li HF, et autres
Publié: (2015)

Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics
par: Li N, et autres
Publié: (2018)

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
par: Zhao JP, et autres
Publié: (2017)

Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies
par: Gopal S, et autres
Publié: (2013)

The need for structural and community interventions to support HIV care and harm reduction for people who inject drugs in Kenya
par: A. Guise, et autres
Publié: (2015)

Intoxicación por Haloperidol (Haldol)
par: Filippa,Rolando, et autres
Publié: (1976)

Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
par: Li H, et autres
Publié: (2018)

Number of daily measurements needed to estimate habitual step count levels using wrist-worn trackers and smartphones in 212,048 adults
par: Jiali Yao, et autres
Publié: (2021)

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
par: Zhang H, et autres
Publié: (2016)